The Breast

Yen & Jaffe's Reproductive Endocrinology

Volumn , Issue , 2009, Pages 235-248

  Barbieri, Robert L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884095326     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-4907-4.00010-3     Document Type: Chapter

References (191)

1. Mauvais-Jarvis P., Kutten F., Gompel A. Estradiol-progesterone interaction in normal and pathologic breast cells. Ann N Y Acad Sci 1986, 464:152-167.
2. Andler W., Zachmann M. Spontaneous breast development in an adolescent girl with testicular feminization after castration in early childhood. J Pediatr 1979, 94:304-305.
3. Naftolin F., Pujol-Amat P., Corker C.S., et al. Gonadotropins and gonadal steroids in androgen insensitivity syndrome: effects of castration and sex steroid administration. Am J Obstet Gynecol 1983, 147:491-496.
4. Rosen J.M., Humphreys R., Krnacik S., et al. The regulation of mammary gland development by hormones, growth factors and oncogenes. Prog Clin Biol Res 1994, 387:95-111.
5. Dixon J.M., Mansel R.E. Congenital problems and aberrations of normal breast development and involution. Br Med J 1994, 309. 797-780.
6. Master S.R., Hartman J.L., D'Cruz C.M., et al. Functional microarray analysis of mammary organogenesis reveals a developmental role in adaptive thermogenesis. Mol Endocrinol 2002, 16:1185-1203.
7. Rigg L.A., Yen S.S.C. The pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol 1977, 129:454-458.
8. Neville M.C., Casey C., Hay W.W. Endocrine regulation of nutrient flux in the lactating woman: do the mechanisms differ from pregnancy?. Adv Exp Med Biol 1994, 352:85-98.
9. Brun del Re R., Del Pozo E., De Grandi P., et al. Prolactin inhibition and suppression of puerperal lactation by CB 154: a comparison with estrogen. Obstet Gynecol 1973, 41:884-890.
10. McNeilly A.S., Robinson C.A.F., Houston M.J., et al. Release of oxytocin and prolactin in response to suckling. Br Med J 1983, 286:257-259.
11. Cosman D. A new cytokine receptor superfamily. Trends Biochem Sci 1990, 15:265-269.
12. Yamashita H., Nevalainen M.T., Xu J., et al. Role of serine phosphorylation of STAT5a in prolactin stimulated beta casein gene expression. Mol Cell Endocrinol 2001, 183:151-163.
13. Aoki N., Matsuda T. A cytosolic protein-tyrosine phosphatase PTP1β specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J Biol Chem 2000, 275:39718-39726.
14. Schmitt-Ney M., Doppler W., Ball R.K., et al. β-Casein gene promoter activity is regulated by the hormone mediated relief of transcriptional repression and a mammary-gland-specific nuclear factor. Mol Cell Biol 1991, 11:3745-3755.
15. Schmitt-Ney M., Happ B., Hofer P. Mammary gland-specific nuclear factor activity is positively regulated by lactogenic hormones and negatively by milk stasis. Mol Endocrinol 1992, 6:1988-1997.
16. The World Health Organization Task Force on Methods for the Natural Regulation of Fertility. Multinational study of breast feeding and lactational amenorrhea. Fertil Steril 1998, 70:461-471.
17. Rahman M., Mascie-Taylor C.G., Rosetta L. The duration of lactational amenorrhea in urban Bangladeshi women. J Biosocial Sci 2002, 34:75-89.
18. Wasalathanthri S., Tennekoon K.H. Lactational amenorrhea and some of their determinants: a comparison of well-nourished and undernourished women. Fertil Steril 2001, 76:317-325.
19. Li W., Qiu Y. Relation of supplementary feeding to resumptions of menstruation and ovulation in lactating postpartum women. Chin Med J 2007, 120:868-870.
20. Valeggia C., Ellison P.T. Lactational amenorrhea in well-nourished Toba women of Formosa, Argentina. J Biol Sci 2004, 36:573-595.
21. Campbell O.M.R., Gray R.H. Characteristics and determinants of postpartum ovarian function in women in the United States. Am J Obstet Gynecol 1993, 169:55-60.
22. Campino C., Ampuero S., Diaz S., et al. Prolactin bioactivity and the duration of lactational amenorrhea. J Clin Endocrinol Metab 1994, 79:970-974.
23. Perheentupa A., Ruokonen A., Tapanainen J.S. Transdermal estradiol treatment suppresses serum gonadotropins during lactation without transfer into breast milk. Fertil Steril 2004, 82:903-907.
24. Barragan J.C., Brotons J., Ruiz J.A., Acien P. Experimentally induced endometriosis in rats: effect on fertility and the effects of pregnancy and lactation on the ectopic endometrial tissue. Fertil Steril 1992, 58:1215-1219.
25. London S.J., Colditz G.A., Stampfer M.J., et al. Lactation and risk of breast cancer in a cohort of US women. Am J Epidemiol 1990, 132:17-26.
26. Missmer S.A., Hankinson S.E., Spiegelman D., et al. Reproductive history and endometriosis among premenopausal women. Obstet Gynecol 2004, 104:965-974.
27. Stuebe A.M., Rich-Edwards J.W., Willett W.C., et al. Duration of lactation and incidence of type 2 diabetes. JAMA 2005, 294:2601-2610.
28. Karlson E.W., Mandl L.A., Hankinson S.E., et al. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis. Arthitis Rheum 2004, 50:3458-3467.
29. Kochenour N.K. Lactation suppression. Clin Obstet Gynecol 1980, 23:1045-1059.
30. Taneykoon M., Dusitsin N., Chalapati S., et al. Effects of hormonal contraceptives on milk volume and infant growth. Contraception 1984, 30:505-522.
31. Lonnerdal B., Forsum E., Hambraeus L. Effect of oral contraceptives on composition and volume of breast milk. Am J Clin Nutr 1980, 33:816-824.
32. Nilsson S., Mellbin T., Hofvander Y., et al. Long term follow up of children breast fed by mothers using oral contraceptives. Contraception 1986, 34:443-457.
33. Schiappacasse V., Diaz S., Zepeda A., et al. Health and growth of infants breastfed by Norplant contraceptive implant users: a six-year follow-up study. Contraception 2002, 66:57-65.
34. Shaamash A.H., Sayed G.H., Hussein, et al. A comparative study of the levonorgestrel releasing intrauterine system versus the copper intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Contraception 2005, 72:346-351.
35. Diaz S. Contraceptive implants and lactation. Contraception 2002, 65:39-46.
36. Morgans D. Bromocriptine and postpartum lactation suppression. Br J Obstet Gynecol 1995, 102:851-853.
37. Comabella M., Alvarez-Sabin J., Rovira A., et al. Bromocriptine and postpartum cerebral angiopathy: a causal relationship?. Neurology 1996, 46:1754-1756.
38. Iffy L., Lindenthal J., Mcardle J.J., et al. Severe cerebral accidents postpartum in patients taking bromocriptine for milk suppression. Isr J Med Sci 1996, 32:309-312.
39. Schmitt-Ney M., Doppler W., Ball R.K., et al. β-Casein gene promoter activity is regulated by the hormone mediated relief of transcriptional repression and a mammary-gland-specific nuclear factor. Mol Cell Biol 1991, 11:3745-3755.
40. Schmitt-Ney M., Happ B., Hofer P. Mammary gland-specific nuclear factor activity is positively regulated by lactogenic hormones and negatively by milk stasis. Mol Endocrinol 1992, 6:1988-1997.
41. Banapurmath C.R., Banapurmath S., Kesaree N. Successful lactation in surrogate mothers. Indian J Pediatr 1993, 60:693-697.
42. Nemba K. Induced lactation: a study of 37 non-puerperal mothers. J Trop Pediatr 1994, 40:240-242.
43. Biervliet F.P., Maguiness S.D., Hay D.M., et al. Induction of lactation in the intended mother of a surrogate pregnancy. Hum Reprod 2001, 16:581-583.
44. Hallbauer U. Sulpiride use to stimulate lactation. S Afr Med J 1997, 87:774-775.
45. Pearson D., Kaur M., San P., et al. Recovery of pregnancy mediated bone loss during lactation. Bone 2004, 34:570-578.
46. Ziegler J.B., Cooper D.A., Johnson R.O., et al. Postnatal transmission of AIDS-associated retrovirus from mother to infant. Lancet 1985, 1:896-898.
47. Miotti P.G., Taha T.E.T., Kumwenda N.I., et al. HIV transmission through breastfeeding. JAMA 1999, 282:744-749.
48. Mbori-Ngacha D., Ndutai R., John G., et al. Morbidity and mortality in breastfed and formula-fed infants of HIV-1 infected women. JAMA 2001, 286:2413-2420.
49. Palombi L., Marazzi M.C., Voetberg A., et al. Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV. AIDS 2007, 21(Suppl 4):S65-S71.
50. Papathakis P.C., Van Loan M.D., Rollins N.C., et al. Body composition changes during lactation in HIV-infected and HIV-uninfected South African women. J Acquir Immune Defic Syndr 2006, 43:467-474.
51. Cotran R.S., Kumar V., Robbins S.L. Pathologic Basis of Disease 1994, WB Saunders, Philadelphia. ed. 5.
52. Vorherr H. Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture and management. Am J Obstet Gynecol 1986, 154:161-179.
53. Hartmann L.C., Sellers T.A., Frost M.H., et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005, 353:229-237.
54. Pisani P., Parkin D.M., Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer 1993, 55:891-903.
55. Broca P. Traite des Tumeurs 1866, Asselin, Paris.
56. Slattery M.L., Kerber R.A. A comprehensive evaluation of family history and breast cancer risk, the Utah population database. JAMA 1993, 270:1563-1568.
57. Weber B.L., Garber J.E. Family history and breast cancer, probabilities and possibilities. JAMA 1993, 270:1602-1603.
58. Shattuck-Eidens D., McClure M.C., Simard J., et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. JAMA 1995, 273:535-541.
59. Miki Y., Swensen J., Shattuck-Eidens D., et al. Isolation of BRCA1, the 17q-linked breast and ovarian cancer susceptibility gene. Science 1994, 266:66-71.
60. Yang H., Jeffrey P.D., Miller J., et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 2002, 297:1837-1848.
61. Ford D., Easton D.F. The genetics of breast and ovarian cancer. Br J Cancer 1995, 72:805-812.
62. Easton D.F., Ford D., Bishop D.T. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995, 56:265-271.
63. Chen S., Iversen E.S., Friebel T., et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 2006, 24:863-867.
64. Easton D.F., Deffenbaugh A.M., Pruss D., et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer predisposition genes. Am J Hum Genet 2007, 81:873-883.
65. Easton D.F., Ford D., Bishop D.T. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 1995, 56:265-271.
66. Muto M.G., Cramer D.W., Tangir J., et al. Frequency of the BRCA1 185 del AG mutation among Jewish women with ovarian cancer and matched population controls. Cancer Res 1996, 56:1250-1252.
67. Wooster R., Neuhausen S., Manigion J., et al. Localization of a breast cancer susceptibility gene (BRCA2) to chromosome 13q by genetic linkage analysis. Science 1994, 265:2088-2090.
68. Bishop D.T., Cannon-Albright L., McLellan T., et al. Segregation and linkage analysis of 9 Utah breast cancer pedigrees. Genet Epidemiol 1988, 5:151-169.
69. Zakian V.A. ATM related genes: what do they tell us about functions of the human gene?. Cell 1995, 82:685-687.
70. Easton D.F. Cancer risks in A-T heterozygotes. Int J Radiat Biol 1994, 66:s177-s182.
71. Li F.P., Fraumeni J.F., Mulvihill J.J., et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48:5358-5362.
72. Malkin D., Li F.P., Strong L.C., et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990, 250:1233-1238.
73. Ziv E., Cauley J., Morin P.A., et al. Association between the T29 to C polymorphism in the transforming growth factorβ1 gene and breast cancer among elderly white women. JAMA 2001, 285:2895-2963.
74. Easton D.F., Pooley K.A., Dunning A.M., et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093.
75. Kelsey J.L., Gammon M.D., John E.M. Reproductive factors and breast cancer. Epidemiol Rev 1993, 15:36-47.
76. Rosner B., Colditz G., Willet W. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol 1994, 139:819-835.
77. Hseih C.C., Trichopoulos D., Katsouyanni K., et al. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer 1990, 46:796-800.
78. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy. Lancet 1997, 350:1047-1051.
79. Kelsey J.L., Gammon M.D., John E.M. Reproductive factors and breast cancer. Epidemiol Rev 1993, 15:36-47.
80. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and breastfeeding: collaborative analysis of individual data from 47 epidemiologic studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease. Lancet 2002, 360:187-195.
81. Brinton L.A., Schairer C., Hoover R.N., et al. Menstrual factors and risk of breast cancer. Cancer Invest 1988, 6:245.
82. Huang Z., Hankinson S.E., Colditz G.A., et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997, 278:1407-1411.
83. Hankinson S.E., Willett W.C., Manson J.E., et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998, 90:1292-1299.
84. James M.R., Skaar T.C., Lee R.Y., et al. Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo. Endocrinology 2001, 142:1497-1505.
85. Cauley J.A., Lucas F.L., Kuller L.H., et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med 1999, 130:270-277.
86. Key T., Appleby P., Barnes I., Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women. J Natl Cancer Inst 2002, 94:606.
87. Missmer S.A., Eliassen A.H., Barbieri R.L., Hankinson S.E. Endogenous estrogen, androgen and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004, 96:1856.
88. Eliassen A.H., Missmer S.A., Tworoger S.S., et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006, 98:1406-1415.
89. Tworger S.S., Eliassen A.H., Sluss P., et al. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007, 25:1482-1488.
90. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst 1998, 90:1371-1388.
91. Cummings S.R., Eckert S., Krueger K., et al. The effect of raloxifene on the risk of breast cancer in postmenopausal women. JAMA 1999, 281:2189-2197.
92. Cummings S.R., Duong T., Kenyon E., et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002, 287:216-220.
93. The ATAC Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002, 359:2131-2139.
94. Hankinson S.E., Willett W.C., Michaud D.S., et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999, 91:629-634.
95. Hankinson S.E., Willett W.C., Colditz G.A., et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351:1393-1396.
96. Hunter D.P., Kraft P., Jacobs K.B., et al. A genome-wide association study identifies alleles in FGF2R associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007, 39:87-94.
97. Marchbanks P.A., McDonald J.A., Wilson H.G., et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002, 346:2025-2032.
98. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormonal contraceptives. Lancet 1996, 347:1713-1727.
99. Chen C., Weiss N.S., Newcomb P., et al. Hormone replacement therapy in relation to breast cancer. JAMA 2002, 287:734-741.
100. Black W.C., Nease R.F., Tosteson A.N. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 1995, 87:720-731.
101. Writing Group for the Women's health Initiative Study Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002, 288:321-333.
102. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 2003, 289:3243-3253.
103. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative. JAMA 2004, 291:1701-1712.
104. Colditz G.A., Egan K.M., Stampfer M.J. Hormone replacement therapy and the risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993, 168:1473-1480.
105. Lyytinen H., Pukkala E., Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006, 108:1354-1360.
106. Li C.I., Malone K.E., Porter P.L., et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003, 289:3254-3263.
107. Kuiper G.G., Enmark E., Pelto-Huikko M., et al. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci 1996, 93:5925-5930.
108. McDonnell D.P., Clemm D.L., Hermann T., et al. Analysis of estrogen receptor function in vitro reveals 3 distinct classes of antiestrogens. Mol Endocrinol 1995, 9:659-669.
109. Ornate S.A., Tsai S.Y., Tsai M.J., et al. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270:1354-1357.
110. Baracat E., Haidar F., Lopez F.J., et al. Estrogen activity and novel tissue selectivity of delta 8,9-dehydroestrone sulphate in postmenopausal women. J Clin Endocrinol Metab 1999, 84:2020-2027.
111. Dey M., Lyttle C.R., Pickar J.H. Recent insights into the varying activity of estrogens. Maturitas 2000, 34(Suppl 2):S25-S33.
112. Fournier A., Berrino F., Riboli E., et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005, 114:448-454.
113. Fuchs C.S., Stampfer M.J., Colditz G.A., et al. Alcohol consumption and mortality among women. N Engl J Med 1995, 332:1245-1250.
114. Reichman M.E., Judd J.T., Longcope C. Effects of alcohol consumption on plasma and urinary hormone concentration in premenopausal women. J Natl Cancer Inst 1993, 85:722-727.
115. Dorgan J.F., Baer D.J., Albert P.S., et al. Serum hormones and the alcohol-breast cancer association in postmenopausal women. J Natl Cancer Inst 2001, 93:710-715.
116. Singletary K.W., Gapstur S.M. Alcohol and breast cancer. JAMA 2001, 286:2143-2151.
117. Zhang S., Hunter D.J., Hankinson S.E., et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999, 281:1632-1637.
118. Ginsburg E.S., Walsh B.W., Shea B.F., et al. The effects of ethanol on the clearance of estradiol in postmenopausal women. Fertil Steril 1995, 63:1227-1230.
119. Ginsburg E.S., Mello N.K., Mendelson J.H., et al. Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA 1996, 276:1747-1751.
120. Morris A.D., Morris R.D., Wilson J.F., et al. Breast conserving therapy vs. mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. Cancer J Sci Am 1997, 3:6-12.
121. Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic or immunotherapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992, 339(1-15):71-85.
122. Krag D., Weaver D., Ashikaga T., et al. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med 1998, 339:941-946.
123. Giuliano A.E., Jones R.C., Brennan M., et al. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997, 15:2345-2350.
124. Adams H.K., Patterson J.S., Kemp J.V. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep 1980, 64:761-764.
125. Jordan V.C., Fritz N.F., Tormey D.C. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node positive patients with breast cancer. Cancer Res 1987, 47:624-630.
126. Kemp J.V., Adam H.K., Wakeling A.E. Identification and biological activity of tamoxifen metabolites in human serum. Biochem Pharmacol 1983, 32:2045-2052.
127. Fabian C., Tilzer L., Sternson L. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm Drug Dispos 1981, 2:381-390.
128. Wakeling A.E., Slater S.R. Estrogen-receptor binding and biological activity of tamoxifen and its metabolites. Cancer Treat Rep 1980, 64:741-744.
129. Saki F., Cheix F., Clavel M. Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J Endocrinol 1978, 76:219-226.
130. Love R.R., Wiebe D.P., Newcombe P.A. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991, 115:860-864.
131. Luciani L., Oriana S., Spatti G. Hormonal and receptor status in postmenopausal women with endometrial carcinoma before and after treatment with tamoxifen. Tumori 1984, 70:189-192.
132. Boccardo F., Bruzzi P., Rubagotti A. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 1981, 38:281-285.
133. Love R.R., Mazess R.B., Barden H.S. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992, 326:852-856.
134. Gottardis M.M., Robinson S.P., Satyaswaroop P.G., et al. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988, 48:812-814.
135. Coezy E., Borgna J.L., Rochefort H. Tamoxifen and metabolites in MCF-7 cells. Correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982, 42:317-323.
136. Imai Y., Leung C.K.H., Friesen H.G. Epidermal growth factor receptors and effect of epidermal growth factor on growth of human breast cancer cells in long term tissue culture. Cancer Res 1982, 42:4394-4398.
137. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998, 351:1451-1455.
138. Fisher B., Redmond C. New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J Natl Cancer Inst 1991, 83:1278-1280.
139. National Cancer Institute Adjuvant therapy of breast cancer tamoxifen update. US Department of Health and Human Services, National Institutes of Health, Public Health Service November 30, 1995, National Cancer Institute clinical announcement, Bethesda, MD.
140. Santen R.J. Long term tamoxifen therapy: can an antagonist become an agonist? (Editorial). J Clin Endocrinol Metab 1996, 81:2027-2029.
141. Rutqvist L.E., Johansson H., Signomklao T., et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995, 87:645-651.
142. Fisher J.B., Costantino J.P., Redmond C.K. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst 1994, 86:527-537.
143. Daniel Y., Inbar M., Bar-Am A., et al. The effects of tamoxifen treatment on the endometrium. Fertil Steril 1996, 65:1083-1089.
144. Jordan V.C., Fritz N.F., Langan-Fahey S. Alteration of endocrine parameters in premenopausal women with breast cancer with long term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 1999, 83:1488-1491.
145. Groom G.V., Griffiths K. Effects of the anti-estrogen tamoxifen on plasma levels of luteinizing hormone, follicle stimulating hormone, prolactin, estradiol and progesterone in normal premenopausal women. J Endocrinol 1976, 70:421-428.
146. Sherman B.M., Chapler F.K., Crickard K. Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. J Clin Invest 1979, 64:398-404.
147. Boccardo F., Blamey R., Klijn J.C.M., et al. LHRH-agonist and tamoxifen versus LHRH-agonist alone in premenopausal women with advanced breast cancer. Proc Am Soc Clin Oncol 1999, 88:110a.
148. Klijn J.G.M., Beex L.V.A.M., Mauriac L., et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000, 11:903-911.
149. Sato M., Rippy M.K., Bryant H.U. Raloxifene, tamoxifen, nafoxidene or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996, 10:905-912.
150. Hayes D.F., Van Zyl J.A., Hacking A., et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995, 13:2556.
151. Osborne C.K., Coronado-Heisohn E.B., Hilsenbeck S.G., et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995, 87:746.
152. Osborne C.K. A double blind randomized trial comparing the efficacy and tolerability of fulvestrant with Arimidex in postmenopausal women with advanced breast cancer. Br Cancer Res Treat 2000, 64:27.
153. Black L.J., Sato M., Rowley E.R., et al. Raloxifene prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994, 93:63-69.
154. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. J Clin Oncol 2000, 18:3758.
155. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001, 19:2596-2602.
156. The Breast International Collaborative Group A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757.
157. Duffy S., Jackson T.L., Lansdown M., et al. Hum Reprod 2006, 21:545-553.
158. Baum M. The Arimidex, Tamoxifen Alone or in Combination adjuvant breast cancer trial in postmenopausal women (ATAC). Breast Cancer Treat 2001, 69:210-219.
159. Cuzick J., Sasieni P., Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. Br J Cancer 2006, 27:460-464.
160. Rebbeck T.R., Friebel T., Lynch H.T., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004, 22:1055.
161. Muijers-Heijboer H., van Geel B., van Putten W., et al. Breast cancer after prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001, 345:159-164.
162. Hartmann L.C., Schaid D.J., Woods J.E., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999, 340:77-84.
163. Rebbeck T.R., Levin A.M., Eisen A., et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999, 91:1475-1479.
164. Metcalfe K., Lynch H.T., Ghadirian P., et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004, 22:2328.
165. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346:1616-1622.
166. Medeiros F., Muto M.G., Lee Y., et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006, 30:230-236.
167. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896, 2:104-106.
168. Scottish Cancer Trials Breast Group and ICRF Breast Unit Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993, 341:1293-1298.
169. Boccardo F., Rubagotti A., Amoroso D., et al. Cyclophosphamide, methotrexate and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000, 18:2718-2725.
170. Adjuvant Breast Cancer Trials Collaborative Group Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst 2007, 99:516-525.
171. Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996, 14:1718-1729.
172. Goldhirsch A., Gelber R.D., Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann Oncol 1990, 1:183-188.
173. Bianco A.R., Del Mastro L., Gallo C. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer 1991, 63:799-803.
174. Pagani O., O'Neill A., Castiglione M., et al. Prognostic impact of amenorrhea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement. Eur J Cancer 1998, 34:632-640.
175. Col N.F., Hirota L.K., Orr R.K., et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001, 19:2357-2363.
176. O'Meara E.S., Rossing M.A., Daling J.R., et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001, 93:754-762.
177. Holmberg L., Anderson H. HABITS (hormonal replacement therapy after breast cancer: is it safe?) a randomized comparison: trial stopped. Lancet 2004, 363:453-455.
178. The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society. Treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrinol Metab 1998, 83:1993-2000.
179. Ives A., Saunders C., Bulsara M., Semmens J. Pregnancy after breast cancer: population based study. BMJ 2007, 334:194-199.
180. Blakely L.J., Buzdar A.U., Lozada J.A., et al. Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer 2004, 100:465-469.
181. Sutton R., Buzdar A.U., Hortobagyi G.N. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 1990, 65:847-850.
182. Ariel I.M., Kempner R. The prognosis of patients who become pregnant after mastectomy for breast cancer. Int Surg 1989, 74:185-187.
183. Harvey J.C., Rosen P.P., Ashikari R., et al. The effect of pregnancy on the prognosis of carcinoma of the breast following mastectomy. Surg Gynecol Obstet 1981, 153:723-725.
184. Von Schoultz E., Johannsson H., Wilking N., Rutqvist L.E. Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 1995, 13:430-434.
185. Abe O., Abe R., Enomoto K., et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival. Lancet 2005, 365:1687-1717.
186. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 2005, 23:1636-1643.
187. Dorgan J.F., Longcope C., Franz C., et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002, 94:606-616.
188. Guray M., Sahin A.A. Benign breast diseases: classification, diagnosis and management. Oncologist 2006, 11:435-449.
189. Hankinson S.E., Eliassen A.H. Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk. J Steroid Biochem Mol Biol 2007, 106:24-30.
190. Stuebe A.M., Rich-Edwards J.W., Willett W.C., et al. Duration of lactation and incidence of type 2 diabetes. JAMA 2005, 294:2601-2610.
191. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors. J Clin Oncol 2005, 23:619-629.